PER Shares Percheron Therapeutics Limited
ASX · ASXLast in our picks 2026-10-22 — not in the current list; analysis below is from that screen
Phase II initiation and product release offer defined catalysts for a small-cap valuation reset.
Signal breakdown
- ▸Edison valuation support and planned Phase II trial initiation.
- ▾Below 50-day MA (-10.91%)
Is PER a buy right now?
Trend: PER is trading RSI 38 — neutral momentum, with a 3-month return of +0.00%.
Valuation & quality: Percheron Therapeutics Limited trades on forward P/E -0.6, price-to-book 0.60; fundamentals show net margin 0.0%, return on equity -54.7%, revenue growth -54.2% year on year.
Our screen: WATCH (score 0) — Phase II initiation and product release offer defined catalysts for a small-cap valuation reset.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -100.00% | — | — | — | — | — | — | — |
Fundamentals
Technical signals
About Percheron Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.